Morality in DATATOP:A Multicenter Trial in Early Parkinson's Disease
Parkinson Study Group, Ann Neurol 43:318-3251998., , 1998
Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Subjects Not Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:29-361996., , 1996
Impact of Deprenyl and Toxopherol Treatment on Parkinson's Disease in DATATOP Patients Requiring Levodopa
Parkinson Study Group, Ann Neurol 39:37-451996., , 1996
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 328:176-1831993., , 1993
The Antiparkinson Efficacy of Deprenyl Derives from Transient Improvement that is Likely to be Symptomatic
Ann Neurol 32:795-798, Schulzer,M.,et al, 1992
The Free Radical Hypothesis in Idiopathic Parkinsonism:Evidence Against It
Ann Neurol 32:799-803, Calne,D.B., 1992
Pyramid Sale in the Bucket Shop:DATATOP Bottoms Out
Neurol 40:1337-1339, Landau,W.M., 1990
Variable Expression of Parkinson's Disease:A Base-line Analysis of the DATATOP Cohort
Neurol 40:1529-1534, Jankovic,J.,et al, 1990
Current Theories on the Cause of Parkinson's Disease
JNNP Suppl (June) 52:13-17989., Langston,J.W., 1989
Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease
The Parkinson Study Group, NEJM 321:1364-13711989., , 1989
DATATOP:A Multicenter Controlled Clinical Trial in Early Parkinson's Disease
Parkinson Study Group, Arch Neurol 46:1052-10601989., , 1989
Single Photon Emission Computed Tomography/Positron Emission Tomography Molecular Imaging for Parkinsonism: A Fast-Developing Field
Ann Neurol 90:711-719, Verger, A.,et al, 2021
Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Court
JAMA Neurol 74:933-940,901, Jennings, D.,et al, 2017
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Functional Imaging in Parkinson Disease
Neurol 70:1478-1488, Nandhagopal,R.,et al, 2008
Functional Abnormalities Underlying Pathological Gambling in Parkinson Disease
Arch Neurol 65:1604-1611, Cilia,R.,et al, 2008
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinsons Disease
NEJM 356:39-46, Zanettini,R.,et al, 2007
Dopamine Agonists and the Risk of Cardiac Valve Regurgitation
NEJM 356:29-38, Schade,R.,et al, 2007
Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonsits in Parkinson Disease
Arch Neurol 64:377-380, Dewey,R.B.,Jr, et al, 2007
Genetics of Parkinsons Disease and Parkinsonism
Ann Neurol 60:389-398, Hardy,J.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Treatment of Parkinson's Disease with Pergolide and Relation to Restrictive Valvular Heart Disease
Lancet 363:1179-1183, Van Camp,G.,et al, 2004
Idiopathic Hyposmia As a Preclinical Sign of Parkinson's Disease
Ann Neurol 56:173-181,169, Ponsen,M.M.,et al, 2004
Levodopa and the Progression of Parkinson's Disease
NEJM 351:2498-2508, The Parkinson Study Group, 2004
[123I]b-CIT SPECT is a Useful Method for Monitoring Dopaminergic Degeneration in Early Stage Parkinson's Disease
JNNP 74:294-298,287, Winogrodzka,A.,et al, 2003
Heart Valvular Disease in Patients with Parkinson's Disease Treated with High-Dose Pergolide
Neurol 61:859-861, VanCamp,G.,et al, 2003
Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease Progression
JAMA 287:1653-1661, Parkinson Study Group, 2002
Subclinical Dopaminergic Dysfunction in Asymptomatic Parkinson's Disease Patients' Relatives with a Decreased Sense of Smell
Ann Neurol 50:34-41, Berendse,H.W.,et al, 2001
[123I]Beta-CIT SPECT Imaging Assessment of the Rate of Parkinson's Disease Progression
Neurol 57:2089-2094, Marek,K.,et al, 2001
Striatal Dopamine Trnasporter Binding Assessed by [I-123]IPT and Single Photon Emission Computed tomography in Patients with Early Parkinson's Disease, Implications for a Preclinical Diagnosis
Arch Neurol 57:205-208, Schwarz,J.,et al, 2000
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Decreased SPECT[123I]B-CIT Striatal Uptake Correlates with Symptom Severity in Parkinson's Disease
Ann Neurol 38:589-598, Seibyl,J.P.,et al, 1995
Multiple System Atrophy & Prog Supranuc Palsy, Dimin Striatal D2 Dopamine Receptor Act by SPECT
Arch Neurol 50:513-516, vanRoyen,E.,et al, 1993
123I-iodobenzamide-SPECT Predicts Dopaminergic Responsiveness in patients with De Dovo Parkinsonism
Neurol 42:556-561, Schwarz,J.,et al, 1992
Advances in Neurology
NEJM 326:1608-1616, 1671-16761992., Gilman,S., 1992
Clinical Cases-Dx:Functional Approach to Neuroanatomy pp 477-490 Earl Lawrence House
McGraw Hill 1967., , 1967